Home
User Guide
What's in a MalaCard Search Guide Our Sources
Analysis Tools
GeneCards GeneAnalytics GeneAlaCart PathCards VarElect TGex
News and Views Disease Lists/Categories
About
About MalaCards Our Publications Weizmann Institute LifeMap Discovery® Terms of Use MalaCards Team
MCID: ISC004
MIFTS: 66

Ischemia

Categories: Blood diseases, Cardiovascular diseases, Metabolic diseases
Genes Variations Tissues Related diseases Publications Pathways Symptoms & Phenotypes Drugs
Sources

Aliases & Classifications for Ischemia

About this section

MalaCards integrated aliases for Ischemia:

Name: Ischemia 12 55 44 15 73
Acute Coronary Syndrome 73

Classifications:

MalaCards categories:
Global: Metabolic diseases
Anatomical: Cardiovascular diseases Blood diseases
See all MalaCards categories (disease lists)


External Ids:

Disease Ontology 12 DOID:326
MeSH 44 D007511
NCIt 50 C34738
SNOMED-CT 68 52674009
Sources

Summaries for Ischemia

About this section
Disease Ontology : 12 A vascular disease that is characterized by a restriction in blood supply to tissues.

MalaCards based summary : Ischemia, also known as acute coronary syndrome, is related to retinal ischemia and limb ischemia, and has symptoms including muscle weakness, polydipsia and angina pectoris. An important gene associated with Ischemia is ENSG00000278514 (), and among its related pathways/superpathways are PI3K-Akt signaling pathway and Development HGF signaling pathway. The drugs Carvedilol and Probucol have been mentioned in the context of this disorder. Affiliated tissues include brain, heart and endothelial, and related phenotypes are Synthetic lethal with MLN4924 (a NAE inhibitor) and Synthetic lethal with MLN4924 (a NAE inhibitor)

Wikipedia : 76 Ischemia or ischaemia is a restriction in blood supply to tissues, causing a shortage of oxygen that is... more...

Sources

Related Diseases for Ischemia

About this section

Diseases related to Ischemia via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 781)
# Related Disease Score Top Affiliating Genes
1 retinal ischemia 33.9 CASP3 CXCL12 VEGFA
2 limb ischemia 33.9 ACE CXCL12 NOS3 VEGFA
3 coronary artery anomaly 32.7 ACE GJA1 NOS3 PON1
4 vascular disease 32.5 ACE HMOX1 MPO NOS3 PON1 VEGFA
5 microvascular complications of diabetes 5 32.2 ACE NOS3 PON1 VEGFA
6 myocardial infarction 32.1 ACE CASP3 CXCL12 GJA1 MPO NOS3
7 arteries, anomalies of 31.1 ACE NOS3 PON1 VEGFA
8 peripheral artery disease 30.7 ACE NOS3 VEGFA
9 diabetes mellitus 30.6 ACE EPO NOS3 PON1 SOD2 VEGFA
10 heart disease 30.6 ACE GJA1 NOS3 PON1 VEGFA
11 stroke, ischemic 30.5 ACE CASP3 NOS3 PON1
12 renovascular hypertension 30.3 ACE HMOX1 NOS3
13 vascular dementia 30.3 ACE PON1 VEGFA
14 chronic kidney failure 30.2 ACE EPO NOS3 PON1
15 alzheimer disease 30.0 CASP3 CASP9 CDK5 HMOX1 MPO NOS3
16 pulmonary edema 30.0 ACE HMOX1 NOS3
17 arteriovenous fistula 30.0 EPO HMOX1
18 diabetic neuropathy 29.6 ACE EPO SOD2 VEGFA
19 hepatopulmonary syndrome 29.6 HMOX1 NOS3 VEGFA
20 varicocele 29.5 CASP3 CASP9 NOS3
21 transient cerebral ischemia 12.5
22 brain ischemia 12.5
23 critical limb ischemia 12.5
24 chronic myocardial ischemia 12.2
25 chronic intestinal vascular insufficiency 11.6
26 cerebral hypoxia 11.4
27 hypoxia 11.4
28 ischemic heart disease 11.4
29 acute vascular insufficiency of intestine 11.3
30 legg-calve-perthes disease 11.3
31 arterial calcification, generalized, of infancy, 1 11.3
32 nonarteritic anterior ischemic optic neuropathy 11.3
33 vertebrobasilar insufficiency 11.3
34 myocardial stunning 11.2
35 polyarteritis nodosa, childhood-onset 11.2
36 central retinal vein occlusion 11.2
37 fibromuscular dysplasia 11.2
38 calciphylaxis 11.2
39 peripheral nervous system disease 11.2
40 microvascular complications of diabetes 1 11.2
41 microvascular complications of diabetes 2 11.2
42 short bowel syndrome 11.2
43 peritonitis 11.2
44 exudative vitreoretinopathy 1 11.2
45 microvascular complications of diabetes 3 11.2
46 microvascular complications of diabetes 4 11.2
47 microvascular complications of diabetes 6 11.2
48 microvascular complications of diabetes 7 11.2
49 ischemic colitis 11.2
50 cerebral atherosclerosis 11.2

Graphical network of the top 20 diseases related to Ischemia:



Diseases related to Ischemia
Sources

Symptoms & Phenotypes for Ischemia

About this section

UMLS symptoms related to Ischemia:


muscle weakness, polydipsia, angina pectoris, anoxemia

GenomeRNAi Phenotypes related to Ischemia according to GeneCards Suite gene sharing:

26
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Synthetic lethal with MLN4924 (a NAE inhibitor) GR00250-A-1 9.77 ACE CASP3 CASP9 HMOX1 MPO NOL3
2 Synthetic lethal with MLN4924 (a NAE inhibitor) GR00250-A-2 9.77 ACE CASP3 CASP9 HMOX1 MPO NOL3

MGI Mouse Phenotypes related to Ischemia:

46 (show all 15)
# Description MGI Source Accession Score Top Affiliating Genes
1 cardiovascular system MP:0005385 10.41 ACE ADORA3 CASP3 CASP9 CXCL12 EGR1
2 homeostasis/metabolism MP:0005376 10.38 ACE ADORA3 CASP3 CDK5 EGR1 EPO
3 cellular MP:0005384 10.37 CASP3 CASP9 CXCL12 EGR1 EPO GJA1
4 hematopoietic system MP:0005397 10.34 ACE ADORA3 CASP3 CASP9 CXCL12 EGR1
5 behavior/neurological MP:0005386 10.33 ACE ADORA3 CASP3 CDK5 EGR1 GJA1
6 immune system MP:0005387 10.3 ACE ADORA3 CASP3 CASP9 CXCL12 EGR1
7 mortality/aging MP:0010768 10.21 ACE CASP3 CASP9 CDK5 CXCL12 EGR1
8 endocrine/exocrine gland MP:0005379 10.16 ACE CASP3 CASP9 EGR1 GJA1 HMOX1
9 muscle MP:0005369 10.06 CASP3 CXCL12 EPO GJA1 HMOX1 MPO
10 integument MP:0010771 10.03 ADORA3 CASP3 CDK5 EGR1 EPO GJA1
11 liver/biliary system MP:0005370 10.01 ACE CXCL12 EGR1 EPO HMOX1 NOS3
12 nervous system MP:0003631 10 CASP3 CASP9 CDK5 CXCL12 EGR1 GJA1
13 renal/urinary system MP:0005367 9.76 ACE ADORA3 CASP3 HMOX1 NOS3 PRKAA2
14 reproductive system MP:0005389 9.61 ACE CASP3 CXCL12 EGR1 GJA1 HMOX1
15 respiratory system MP:0005388 9.36 ADORA3 CASP3 CASP9 CDK5 EGR1 EPO
Sources

Drugs & Therapeutics for Ischemia

About this section

Drugs for Ischemia (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 1233)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Carvedilol Approved, Investigational Phase 4,Phase 3,Phase 2 72956-09-3 2585
2
Probucol Approved, Investigational Phase 4 23288-49-5 4912
3
Aspirin Approved, Vet_approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1 50-78-2 2244
4
Cilostazol Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 73963-72-1 2754
5
Sevoflurane Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 28523-86-6 5206
6
Capsaicin Approved Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable,Early Phase 1 404-86-4 1548943
7
Angiotensin II Approved, Investigational Phase 4,Phase 3,Phase 2,Not Applicable 11128-99-7, 68521-88-0, 4474-91-3 172198 65143
8
Valsartan Approved, Investigational Phase 4,Phase 3,Phase 2,Not Applicable 137862-53-4 60846
9
Clopidogrel Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable 113665-84-2, 120202-66-6 60606
10
Ticlopidine Approved Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1,Not Applicable 55142-85-3 5472
11
Heparin Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 9005-49-6 772 46507594
12
Nadroparin Approved, Investigational Phase 4
13
Atenolol Approved Phase 4,Phase 3,Not Applicable 29122-68-7 2249
14
Zinc Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 7440-66-6
15
Benzocaine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 94-09-7, 1994-09-7 2337
16 tannic acid Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
17
Nimodipine Approved, Investigational Phase 4,Phase 2,Not Applicable 66085-59-4 4497
18
Esmolol Approved Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable 103598-03-4, 81147-92-4 59768
19
Dexmedetomidine Approved, Vet_approved Phase 4,Phase 3,Phase 2,Not Applicable,Early Phase 1 113775-47-6 68602 5311068
20
Ranolazine Approved, Investigational Phase 4,Phase 3,Phase 2,Not Applicable 142387-99-3, 95635-55-5 56959
21
Bevacizumab Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1 216974-75-3
22
Clonidine Approved Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable 4205-90-7 2803
23
Sotalol Approved Phase 4,Phase 3,Not Applicable 959-24-0, 3930-20-9 5253
24
Amiodarone Approved, Investigational Phase 4,Phase 3,Not Applicable,Early Phase 1 1951-25-3 2157
25
Rivaroxaban Approved Phase 4,Phase 2,Phase 3,Not Applicable 366789-02-8
26
Ranibizumab Approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 347396-82-1 459903
27
Sirolimus Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 53123-88-9 46835353 6436030 5284616
28
Miconazole Approved, Investigational, Vet_approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 22916-47-8 4189
29
Glucosamine Approved, Investigational Phase 4,Phase 3,Phase 2,Not Applicable 3416-24-8 439213
30
Chlorhexidine Approved, Vet_approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 55-56-1 2713 9552079
31
Everolimus Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 159351-69-6 6442177
32 Nutmeg Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
33
Bivalirudin Approved, Investigational Phase 4,Phase 3,Phase 2,Not Applicable 128270-60-0 16129704
34
Triamcinolone Approved, Vet_approved Phase 4,Phase 3,Phase 1,Phase 2 124-94-7 31307
35
Prednisone Approved, Vet_approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 53-03-2 5865
36
Mycophenolic acid Approved Phase 4,Phase 3,Phase 1,Phase 2 24280-93-1 446541
37
Colchicine Approved Phase 4,Phase 3,Phase 2,Not Applicable 64-86-8 6167 2833
38
Acenocoumarol Approved, Investigational Phase 4,Phase 3,Not Applicable 152-72-7 9052 54676537
39
Abciximab Approved Phase 4,Phase 3,Phase 2,Not Applicable 143653-53-6
40
Nicorandil Approved, Investigational Phase 4,Phase 3,Not Applicable 65141-46-0 47528
41
Adenosine Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1 58-61-7 60961
42
Nicardipine Approved, Investigational Phase 4,Phase 3,Early Phase 1 55985-32-5 4474
43
Acarbose Approved, Investigational Phase 4,Phase 3,Not Applicable 56180-94-0 441184
44
Acetylcholine Approved Phase 4,Phase 2,Phase 1,Not Applicable 51-84-3 187
45
Warfarin Approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 81-81-2 6691 54678486
46
Pentoxifylline Approved, Investigational Phase 4,Phase 2,Phase 3,Not Applicable 6493-05-6 4740
47
Irbesartan Approved, Investigational Phase 4,Phase 3 138402-11-6 3749
48
Candesartan cilexetil Approved Phase 4,Phase 3,Not Applicable 145040-37-5 2540
49
Telmisartan Approved, Investigational Phase 4,Phase 2,Phase 3,Not Applicable 144701-48-4 65999
50
Olmesartan Approved, Investigational Phase 4,Phase 2,Not Applicable 144689-63-4, 144689-24-7 158781 130881

Interventional clinical trials:

(show top 50) (show all 10000)
# Name Status NCT ID Phase Drugs
1 Ischemia In Hemodialysed Patients: Ivabradine Versus Carvedilol Unknown status NCT01425164 Phase 4 Ivabradine;Carvedilol
2 Exploratory Study on the Effects of Early Rosuvastatin Treatment in Patients With Acute Ischemic Stroke Unknown status NCT02643784 Phase 4 Rosuvastatin
3 PreventIon of CArdiovascular Events in iSchemic Stroke Patients With High Risk of Cerebral HemOrrhage Unknown status NCT01013532 Phase 4 Cilostazol;Probucol;Aspirin;placebo of cilostazol;placebo of aspirin
4 The Effectiveness and Safety of Butylphthalide Soft Capsules in Secondary Prevention of Ischemic Stroke Trial Unknown status NCT00724724 Phase 4 Butylphthalide Soft Capsules;Aspirin
5 Effects of Sevoflurane in Subanesthetic Concentrations on the Forearm Perfusion Unknown status NCT00526695 Phase 4 Sevoflurane (Preconditioning)
6 Efficacy Study of Huatuo Zaizao Pills in Improving of Neural Function in Acute Ischemic Stroke Unknown status NCT01758536 Phase 4 Huatuo Zaizao Pills
7 Qutenza for Critical Ischaemia in End Stage Renal Failure Unknown status NCT01704339 Phase 4 QUTENZA
8 Optimized Strategy for Diabetic Patients With Critical Limb Ischemia(Part II) (DCLI-II) Unknown status NCT01173094 Phase 4
9 Valsartan Efficacy on Modest Blood Pressure Reduction in Acute Ischemic Stroke Unknown status NCT00874601 Phase 4 Diovan® (valsartan)
10 PreventIon of IMT Progression in iSchemic Stroke Patients With High Risk of Cerebral HemOrrhage-IMT Study Unknown status NCT02483169 Phase 4 cilostazol;Probucol;Aspirin;placebo of cilostazol;Placebo of aspirin
11 Optimized Strategy for Diabetic Patients With Critical Limb Ischemia(Part I) Unknown status NCT01171703 Phase 4
12 Comprehensive Reparative Therapy in Ischemic Stroke COMplex Repair in Ischemic Stroke-Arm Unknown status NCT02581371 Phase 4 Cerebrolysin infusion
13 The Middle East Dual Anti-platelet Treatment in Acute Transient Ischemic Attack Unknown status NCT02144831 Phase 4 anti-thrombotic treatment using Aspirin (ASA 75-325mg) and Clopidogrel (75mg)
14 Safety and Efficacy of Heparin and Nadroparin in the Acute Phase of Ischemic Stroke Unknown status NCT01862978 Phase 4 Heparin;Nadroparin;Placebo
15 Comparison of Peripheral and Cerebral Arterial Flow in Acute Ischemic Stroke: Fimasartan vs. Valsartan vs. Atenolol Unknown status NCT02403349 Phase 4 Fimasartan;Valsartan;Atenolol
16 Comparison of Two Strategies for Glycemic Control in Acute Ischemic Stroke Unknown status NCT00747279 Phase 4 Intensive insulin therapy
17 Efficacy and Safety Study of Nimodipine to Prevent Mild Cognitive Impairment After Acute Ischemic Strokes Unknown status NCT01220622 Phase 4 Nimodipine;Placebo
18 Hemodynamic Response to Intubation Unknown status NCT02844894 Phase 4 Dexmedetomidine;Esmolol;Placebo
19 Preventive Effects of Ginseng Against Atherosclerosis Unknown status NCT02796664 Phase 4
20 Laser Therapy Combined With Intravitreal Aflibercept vs Intravitreal Aflibercept Monotherapy (LADAMO) Unknown status NCT02432547 Phase 4 Aflibercept
21 Effect of Rosuvastatin on Prognosis of Clinical Response in Acute Ischemic Stroke Patients(REPAIRS) Unknown status NCT02484027 Phase 4 Rosuvastatin
22 Sleep Disordered Breathing in Transient Ischemic Attack (TIA)/Ischemic Stroke and Continuous Positive Airway Pressure (CPAP) Treatment Efficacy Unknown status NCT01097967 Phase 4
23 Effect of Ranolazine on Valvular Disease in Patients With Pacemakers Unknown status NCT01979965 Phase 4 Ranolazine (Active drug);Placebo
24 Bevacizumab and Peripheral Retinal Changes on Wide Field Angiography in Diabetic Macular Edema Unknown status NCT02096874 Phase 4 Bevacizumab
25 EPIC (Evaluating Perioperative Ischemia Reduction by Clonidine) Unknown status NCT00335582 Phase 4 clonidine hydrochloride
26 Diagnostic Benefits of HyperQTM vs. Conventional ECG Stress Test. Comparison of HyperQ vs. Stress ECG in Women Before Angiography Unknown status NCT00850486 Phase 4
27 Ranolazine for Improving Symptoms of Palpitations Unknown status NCT01495520 Phase 4 Ranolazine;Placebo
28 Intensive Statin Treatment in Acute Ischemic Stroke Patients With INtracranial Atherosclerosis Unknown status NCT02458755 Phase 4 High-dose statin: Atorvastatin 40mg or Rosuvastatin 20mg
29 Surgical Treatment of Ischemic Mitral Regurgitation Unknown status NCT01368575 Phase 4
30 The Safety and Efficacy Study of High Dose Atorvastatin After Thrombolytic Treatment in Acute Ischemic Stroke Unknown status NCT02452502 Phase 4
31 Medical ANtiarrhythmic Treatment or Radiofrequency Ablation in Ischemic Ventricular Tachyarrhythmias Unknown status NCT02303639 Phase 4 Antiarrhythmic drug therapy
32 A Clinical Trial of Danhong Injection in Treating Acute Ischemic Stroke Unknown status NCT02152280 Phase 4 Danhong Injection;Normal Saline
33 Medical and Endovascular Treatment of Atherosclerotic Renal Artery Stenosis (METRAS Study) Unknown status NCT01208714 Phase 4 Optimal medical therapy
34 Atrial Fibrillation and Ischemic Events With Rivaroxaban in Patients With Stable Coronary Artery Disease Study Unknown status NCT02642419 Phase 4 Rivaroxaban and single antiplatelet drug (aspirin, clopidogrel or prasugrel);Rivaroxaban
35 Evaluation of the "Treat-and-extend" Scheme in Patients With Retinal Vein Occlusion (RVO) With and Without LASER Treatment of Ischaemic Retinal Areas Unknown status NCT02522897 Phase 4 Ranibizumab
36 A Prospective Multicenter Trial Evaluating Helios Biodegradable Polymer SES Safety and Effectiveness in CAD Treatment Unknown status NCT01880879 Phase 4
37 A Study to Evaluate Safety and Efficacy of the ExcelTM Sirolimus Eluting Stent With a Biodegradable Polymer Versus Sirolimus Eluting Stent With Non-Biodegradable Polymer in the Treatment of Patients With de Novo Coronary Artery Lesions Unknown status NCT00825773 Phase 4
38 Safety Study of Melatonin in Stroke Patients Unknown status NCT01863277 Phase 4 Melatonin;placebo
39 Evaluation of the Use of ACOTEC Drug-Eluting Balloon Litos ® in Below-The-Knee Arteries to Treat Critical Limb Ischemia Unknown status NCT02563535 Phase 4
40 Bivalirudin in Stable Ischemic Heart Disease Patients Undergoing PCI Unknown status NCT02787317 Phase 4 bivalirudin;Heparin
41 Revascularization in Heart Failure Trial – REHEAT 2 Unknown status NCT00388245 Phase 4
42 Comparison of Biomatrix and Orsiro Drug Eluting Stent Unknown status NCT02299011 Phase 4 Biomatrix drug eluting stent
43 Effects of the Use of "de Novo" Everolimus in Renal Tranplant Population Unknown status NCT01663805 Phase 4 Everolimus
44 Efficacy of Xience/Promus Versus Cypher in rEducing Late Loss After stENTing Unknown status NCT00698607 Phase 4 6-month clopidogrel therapy;12-month clopidogrel therapy
45 Assess the Penumbra System in the Treatment of Acute Stroke Unknown status NCT01429350 Phase 4 intravenous (IV) recombinant human tissue plasminogen activator (rtPA)
46 Study Tests Whether a Standardized LVR Performed With the Blue Egg Device Improves Cardiopulmonary Exercise Capacity Unknown status NCT00326690 Phase 4
47 Colchicine for Acute Coronary Syndromes Unknown status NCT01906749 Phase 4 Colchicine;Placebo
48 Cerebral Artery Stenosis, Coronary Artery Disease and Arrhythmia Unknown status NCT00247533 Phase 4
49 Ranolazine Loading to Prevent PCI-induced Myocardial Injury Unknown status NCT01491061 Phase 4 Ranolazine;Placebo
50 Rule Out Transcatheter Aortic Valve Thrombosis With Post Implantation Computed Tomography (RETORIC) Unknown status NCT02826200 Phase 4 Acenocoumarol

Search NIH Clinical Center for Ischemia

Cochrane evidence based reviews: ischemia

Sources

Genetic Tests for Ischemia

About this section
Sources

Anatomical Context for Ischemia

About this section

MalaCards organs/tissues related to Ischemia:

41
Brain, Heart, Endothelial, Spinal Cord, Liver, Kidney, Bone
Sources

Publications for Ischemia

About this section

Articles related to Ischemia:

(show top 50) (show all 11884)
# Title Authors Year
1
Soluble regulators of Interleukin-1 signaling: Novel biomarkers for early acute myocardial infarction diagnosis and to predict ischemia/reperfusion injury? ( 30449335 )
2019
2
Corrigendum to "Pretreatment with obestatin reduces the severity of ischemia/reperfusion-induced acute pancreatitis in rats" [Eur. J. Pharmacol. 760 (2015) 113-121]. ( 30554633 )
2019
3
Risk Factors for Post-Acute Coronary Syndrome Depression: A Meta-analysis of Observational Studies. ( 30312193 )
2019
4
Use of prasugrel vs clopidogrel and outcomes in patients with and without diabetes mellitus presenting with acute coronary syndrome undergoing percutaneous coronary intervention. ( 30391067 )
2019
5
Profound bilateral post-partum retinal circulation ischemia in two diabetic mothers with pre-eclampsia. ( 30519670 )
2019
6
Hydrogen Sulfide Donor GYY4137 Acts Through Endothelial Nitric Oxide to Protect Intestine in Murine Models of Necrotizing Enterocolitis and Intestinal Ischemia. ( 30527488 )
2019
7
Long-term exposure to high altitude hypoxia during pregnancy increases fetal heart susceptibility to ischemia/reperfusion injury and cardiac dysfunction. ( 30017521 )
2019
8
Clinical Features and Outcomes of Patients With Acute Mesenteric Ischemia and Concomitant Colon Ischemia: A Retrospective Cohort Study. ( 30502253 )
2019
9
Luteoloside attenuates neuroinflammation in focal cerebral ischemia in rats via regulation of the PPARγ/Nrf2/NF-κB signaling pathway. ( 30502652 )
2019
10
Effect of sevoflurane preconditioning on astrocytic dynamics and neural network formation after cerebral ischemia and reperfusion in rats. ( 30531009 )
2019
11
MiR-34b Protects Against Focal Cerebral Ischemia-Reperfusion (I/R) Injury in Rat by Targeting Keap1. ( 30539753 )
2019
12
Neuroprotective effect of Notch pathway inhibitor DAPT against focal cerebral ischemia/reperfusion 3 hours before model establishment. ( 30539813 )
2019
13
Muscle metaboreflex activation via postexercise ischemia as a tool for teaching cardiovascular physiology for undergraduate students. ( 30540204 )
2019
14
Interleukin 8 targeted contrast echocardiography is effective to evaluate myocardial ischemia-reperfusion injury in the rabbits. ( 30551385 )
2019
15
New fatty dihydropyridines present cardioprotective potential in H9c2 cardioblasts submitted to simulated ischemia and reperfusion. ( 30551405 )
2019
16
Galanin/GalR1-3 system: A promising therapeutic target for myocardial ischemia/reperfusion injury. ( 30551408 )
2019
17
Long noncoding RNA RMRP upregulation aggravates myocardial ischemia-reperfusion injury by sponging miR-206 to target ATG3 expression. ( 30551524 )
2019
18
Type 1 diabetes alters ischemia-induced gene expression. ( 30555789 )
2019
19
Neuroprotective effects of midazolam on focal cerebral ischemia in rats through anti‑apoptotic mechanisms. ( 30431057 )
2019
20
The protective mechanisms of polydatin in cerebral ischemia. ( 30385347 )
2019
21
PPAR gamma agonist, pioglitazone, rescues liver damage induced by renal ischemia/reperfusion injury. ( 30393147 )
2019
22
Painless local pressure application to test microvascular reactivity to ischemia. ( 30399363 )
2019
23
Protein disulfide-isomerase A3 significantly reduces ischemia-induced damage by reducing oxidative and endoplasmic reticulum stress. ( 30399388 )
2019
24
Endothelial cells promote excitatory synaptogenesis and improve ischemia-induced motor deficits in neonatal mice. ( 30308244 )
2019
25
Astrocyte-specific deletion of Kir6.1/K-ATP channel aggravates cerebral ischemia/reperfusion injury through endoplasmic reticulum stress in mice. ( 30315808 )
2019
26
The role of sphingosine 1 phosphate in coronary artery disease and ischemia reperfusion injury. ( 30341893 )
2019
27
Acute lung injury following penile ischemia and reperfusion. ( 30364540 )
2019
28
Sucrose nonfermenting AMPK-related kinase (SNARK) regulates exercise-stimulated and ischemia-stimulated glucose transport in the heart. ( 30256437 )
2019
29
The efficiency of heart protection with HTK or HTK-N depending on the type of ischemia. ( 30265864 )
2019
30
Remote ischemic conditioning protects against endothelial ischemia-reperfusion injury via a glucagon-like peptide-1 receptor-mediated mechanism in humans. ( 30268384 )
2019
31
Achyranthes aspera Linn. alleviates cerebral ischemia-reperfusion-induced neurocognitive, biochemical, morphological and histological alterations in Wistar rats. ( 30223049 )
2019
32
Heat shock protein 70: A promising therapeutic target for myocardial ischemia-reperfusion injury. ( 30132875 )
2019
33
Effect of microRNA-26a on vascular endothelial cell injury caused by lower extremity ischemia-reperfusion injury through the AMPK pathway by targeting PFKFB3. ( 30132885 )
2019
34
Alveolar liquid clearance in lung injury: Evaluation of the impairment of the β2-adrenergic agonist response in an ischemia-reperfusion lung injury model. ( 30171906 )
2019
35
Protective effects of ex-527 on cerebral ischemia-reperfusion injury through necroptosis signaling pathway attenuation. ( 30067864 )
2019
36
Hippo/YAP signaling pathway mitigates blood-brain barrier disruption after cerebral ischemia/reperfusion injury. ( 30092249 )
2019
37
Determination of multipool contributions to endogenous amide proton transfer effects in global ischemia with high spectral resolution in vivo chemical exchange saturation transfer MRI. ( 30058148 )
2019
38
Comparison of One-Year Survival After Acute Coronary Syndrome in Patients ≥75 Years of Age With Versus Without Living With Spouse. ( 30539743 )
2019
39
Low serum levels of CCL2 are associated with worse prognosis in patients with Acute Coronary Syndrome: 2-year survival analysis. ( 30551392 )
2019
40
Prognostic impact of bundle branch block after acute coronary syndrome. Does it matter if it is left of right? ( 30555891 )
2019
41
Potassium levels and risk of in-hospital arrhythmias and mortality in patients admitted with suspected acute coronary syndrome. ( 30282599 )
2019
42
One-year clinical outcomes in older patients with non-ST elevation acute coronary syndrome undergoing coronary angiography: An analysis of the ICON1 study. ( 30287058 )
2019
43
Downregulated microRNA-224 aggravates vulnerable atherosclerotic plaques and vascular remodeling in acute coronary syndrome through activation of the TGF-β/Smad pathway. ( 30317569 )
2019
44
Not only the global longitudinal strain, but we can do more for the non-ST-elevation acute coronary syndrome patients by speckle tracking echocardiography. ( 30336962 )
2019
45
Diagnostic and prognostic value of sex- and age-specific cutpoints for high-sensitivity Troponin T in non-ST-elevation acute coronary syndrome. ( 30352705 )
2019
46
Factors associated with objectively measured exercise participation after hospitalization for acute coronary syndrome. ( 30391064 )
2019
47
Gender Differences in the Rate of 30-Day Readmissions after Percutaneous Coronary Intervention for Acute Coronary Syndrome. ( 30482594 )
2019
48
An Educational and Skill-Building Intervention to Improve Symptom Recognition and Interpretation in Women With Acute Coronary Syndrome: A Pilot Study. ( 30499790 )
2019
49
Factors Associated With Continued Smoking in Lebanese Patients With Acute Coronary Syndrome. ( 30130359 )
2019
50
Reply to the letter "Not only the global longitudinal strain, but we can do more for the non-ST elevation acute coronary syndrome patients by speckle-tracking-echocardiography". ( 30213601 )
2019
Sources

Variations for Ischemia

About this section

Copy number variations for Ischemia from CNVD:

7
# CNVD ID Chromosom Start End Type Gene Symbol CNVD Disease
1 72977 12 89000000 92600000 Copy number GALNT4 Acute coronary syndrome
Sources

Expression for Ischemia

About this section
Search GEO for disease gene expression data for Ischemia.
Sources

Pathways for Ischemia

About this section

Pathways related to Ischemia according to GeneCards Suite gene sharing:

(show all 18)
# Super pathways Score Top Affiliating Genes
1
PI3K-Akt signaling pathway 37
Show member pathways
 12.84 CASP3 CASP9 EPO NOS3 PRKAA2 VEGFA
2
Development HGF signaling pathway 22
Show member pathways
 12.58 CASP3 CASP9 CDK5 EGR1 NOS3
3
Pathways in cancer 37
12.57 CASP3 CASP9 CXCL12 EPO HMOX1 VEGFA
4
Development Angiotensin activation of ERK 22
Show member pathways
 12.46 ADORA3 CASP3 CASP9 CXCL12 EGR1 EPO
5
Sudden Infant Death Syndrome (SIDS) Susceptibility Pathways 1
11.99 CASP3 EGR1 GJA1 VEGFA
6
Brain-Derived Neurotrophic Factor (BDNF) signaling pathway 1
11.92 CASP3 CDK5 EGR1 PRKAA2
7
Fluid shear stress and atherosclerosis 37
11.88 HMOX1 NOS3 PRKAA2 VEGFA
8
LT-BetaR Pathway 64
Show member pathways
 11.67 CASP3 CASP9 CXCL12
9
VEGF Pathway (Tocris) 61
Show member pathways
 11.66 CASP3 CASP9 NOS3
10
HIF-1 signaling pathway 37
11.62 EPO HMOX1 NOS3 VEGFA
11
AGE/RAGE pathway 1
11.55 CASP3 CASP9 NOS3
12
AGE-RAGE signaling pathway in diabetic complications 37
11.55 CASP3 EGR1 NOS3 VEGFA
13
Celecoxib Pathway, Pharmacodynamics 61
11.48 CASP3 CASP9 VEGFA
14
HIF1Alpha Pathway 64
11.42 EPO NOS3 VEGFA
15
Hepatitis C and Hepatocellular Carcinoma 1
11.38 CASP3 CASP9 VEGFA
16
Validated transcriptional targets of AP1 family members Fra1 and Fra2 1
11.11 GJA1 HMOX1 NOS3
17
HIF-1-alpha transcription factor network 1
11.07 CXCL12 EPO HMOX1 VEGFA
18
Corticotropin-releasing hormone signaling pathway 1
10.99 CASP3 CASP9 GJA1 NOS3 PRKAA2
Sources

GO Terms for Ischemia

About this section

Biological processes related to Ischemia according to GeneCards Suite gene sharing:

(show all 30)
# Name GO ID Score Top Affiliating Genes
1 negative regulation of cell proliferation GO:0008285 9.99 ADORA3 GJA1 HMOX1 NOS3 SOD2
2 apoptotic process GO:0006915 9.95 CASP3 CASP9 CDK5 EPO GJA1 HMOX1
3 regulation of apoptotic process GO:0042981 9.93 CASP9 CDK5 EGR1 NOL3
4 negative regulation of gene expression GO:0010629 9.92 ACE GJA1 PRKAA2 VEGFA
5 negative regulation of apoptotic process GO:0043066 9.91 CASP3 EPO HYOU1 MPO NOL3 PRKAA2
6 aging GO:0007568 9.86 CASP9 EPO MPO SOD2
7 neuron migration GO:0001764 9.82 CDK5 CXCL12 GJA1
8 response to estradiol GO:0032355 9.82 CASP3 CASP9 GJA1
9 response to glucose GO:0009749 9.79 CASP3 EGR1 GJA1
10 response to wounding GO:0009611 9.79 ADORA3 CASP3 CDK5
11 regulation of macroautophagy GO:0016241 9.76 CASP3 CDK5 PRKAA2
12 positive regulation of neuron apoptotic process GO:0043525 9.72 CASP3 CASP9 CDK5
13 blood vessel remodeling GO:0001974 9.67 ACE NOL3 NOS3
14 regulation of transcription from RNA polymerase II promoter in response to hypoxia GO:0061418 9.65 EGR1 EPO VEGFA
15 induction of positive chemotaxis GO:0050930 9.64 CXCL12 VEGFA
16 negative regulation of oxidative stress-induced intrinsic apoptotic signaling pathway GO:1902176 9.63 NOL3 SOD2
17 response to lipopolysaccharide GO:0032496 9.63 CASP3 CASP9 EPO GJA1 MPO NOS3
18 regulation of blood pressure GO:0008217 9.62 ACE HMOX1 NOS3 SOD2
19 response to fluid shear stress GO:0034405 9.61 GJA1 NOS3
20 positive regulation of chemokine biosynthetic process GO:0045080 9.6 EGR1 HMOX1
21 positive regulation of axon extension involved in axon guidance GO:0048842 9.58 CXCL12 VEGFA
22 response to cobalt ion GO:0032025 9.57 CASP3 CASP9
23 negative regulation of hypoxia-induced intrinsic apoptotic signaling pathway GO:1903298 9.54 HYOU1 NOL3
24 positive regulation of peptidyl-tyrosine autophosphorylation GO:1900086 9.52 ACE VEGFA
25 glial cell apoptotic process GO:0034349 9.51 CASP3 CASP9
26 leukocyte apoptotic process GO:0071887 9.46 CASP3 CASP9
27 smooth muscle hyperplasia GO:0014806 9.43 HMOX1 NOS3
28 removal of superoxide radicals GO:0019430 9.43 MPO NOS3 SOD2
29 response to ischemia GO:0002931 9.35 CASP9 EGR1 GJA1 HYOU1 NOL3
30 response to hypoxia GO:0001666 9.17 CASP3 CXCL12 EGR1 EPO HMOX1 NOL3

Molecular functions related to Ischemia according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 cysteine-type endopeptidase activity involved in apoptotic process GO:0097153 9.16 CASP3 CASP9
2 death receptor binding GO:0005123 8.96 CASP3 NOL3
3 cysteine-type endopeptidase activity involved in apoptotic signaling pathway GO:0097199 8.62 CASP3 CASP9